NEW YORK (GenomeWeb News) – Lab21 will serve as exclusive distributor of AdnaGen's circulating tumor cell diagnostic assays in the UK and Ireland under an alliance announced today.

AdnaGen's AdnaTest products detect and analyze circulating tumor cells from metastatic breast cancer and metastatic colon cancer. According to the firms, AdnaGen's tests enable detection of a broad range of tumor molecular markers.

Cambridge, UK-based Lab21 said that it expects to launch the tests as a service beginning in October.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.